JP2023547389A - Ｃｆｔｒ調節剤化合物、その組成物及び用途 - Google Patents

Ｃｆｔｒ調節剤化合物、その組成物及び用途 Download PDF

Info

Publication number
JP2023547389A
JP2023547389A JP2023524685A JP2023524685A JP2023547389A JP 2023547389 A JP2023547389 A JP 2023547389A JP 2023524685 A JP2023524685 A JP 2023524685A JP 2023524685 A JP2023524685 A JP 2023524685A JP 2023547389 A JP2023547389 A JP 2023547389A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
aryl
compound
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547389A5 (enExample
Inventor
イ，ミョンジェ
オ，チャンモク
イム，ダミ
キム，キョン－ア
イ，ソルヒ
ジョン，イルジ
リュ，ジェウン
イ，ジュユン
ジョン，イェリン
クォン，ジンソン
ソン，テ－イク
キム，ゴンヒ
キム，ジョンホ
ユン，ジョンミン
ヒ イ，ジン
ユン，ホンチョル
ウ イ，ジョン
パク，ジュンテ
ミ アン，キョン
Original Assignee
イルドン ファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イルドン ファーマシューティカル カンパニー リミテッド filed Critical イルドン ファーマシューティカル カンパニー リミテッド
Publication of JP2023547389A publication Critical patent/JP2023547389A/ja
Publication of JP2023547389A5 publication Critical patent/JP2023547389A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023524685A 2020-10-23 2021-10-22 Ｃｆｔｒ調節剤化合物、その組成物及び用途 Pending JP2023547389A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063104979P 2020-10-23 2020-10-23
US63/104,979 2020-10-23
PCT/IB2021/000710 WO2022084741A1 (en) 2020-10-23 2021-10-22 Cftr modulator compounds, compositions, and uses thereof

Publications (2)

Publication Number Publication Date
JP2023547389A true JP2023547389A (ja) 2023-11-10
JP2023547389A5 JP2023547389A5 (enExample) 2024-10-30

Family

ID=81290147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524685A Pending JP2023547389A (ja) 2020-10-23 2021-10-22 Ｃｆｔｒ調節剤化合物、その組成物及び用途

Country Status (16)

Country Link
US (2) US11827640B2 (enExample)
EP (1) EP4232451A4 (enExample)
JP (1) JP2023547389A (enExample)
KR (1) KR20230096026A (enExample)
CN (1) CN116348468A (enExample)
AR (1) AR123884A1 (enExample)
AU (1) AU2021363703A1 (enExample)
CA (1) CA3196061A1 (enExample)
CL (1) CL2023001139A1 (enExample)
CO (1) CO2023006647A2 (enExample)
IL (1) IL302247A (enExample)
MX (1) MX2023004712A (enExample)
PY (1) PY2193067A (enExample)
TW (1) TW202233620A (enExample)
UY (1) UY39482A (enExample)
WO (1) WO2022084741A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380835B (zh) * 2022-01-06 2022-12-27 南京桦冠生物技术有限公司 一种7-(3,4-二甲氧苯基)-2-吡唑[1,5-a]嘧啶羧酸的制备方法
TW202425990A (zh) * 2022-11-02 2024-07-01 南韓商日東製藥股份有限公司 包含ｃｆｔｒ調節劑化合物之點眼用組成物
CN120097921A (zh) * 2024-07-05 2025-06-06 广东省科学院动物研究所 二氟甲氧基苯基类pde4抑制剂及其应用
CN121609673A (zh) * 2026-02-02 2026-03-06 五邑大学 一种pde4抑制剂及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101993A1 (en) * 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
JP2011506474A (ja) * 2007-12-13 2011-03-03 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
WO2013087805A1 (en) * 2011-12-14 2013-06-20 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mglu5 receptors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178449A (en) 1978-04-17 1979-12-11 American Cyanamid Company Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines
US4281000A (en) 1979-07-09 1981-07-28 American Cyanamid Company Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents
AU651986B2 (en) 1991-04-22 1994-08-11 Otsuka Pharmaceutical Factory, Inc. Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same
CA2465326C (en) * 2001-11-01 2011-03-29 Icagen, Inc. Pyrazolopyrimidines for decreasing ion flow through a voltage-dependent sodium channel
US7449488B2 (en) * 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
JP2004170323A (ja) 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
US20070270408A1 (en) 2003-04-11 2007-11-22 Novo Nordisk A/S Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
WO2005037837A1 (ja) 2003-10-17 2005-04-28 Nippon Kayaku Kabushiki Kaisha 置換２−アミノ−[１，２，４]トリアゾロ[１，５−a]ピリミジン誘導体及びその用途
US7498434B2 (en) 2004-01-14 2009-03-03 Mallinckrodt Inc Two-phase method for the synthesis of selected pyrazolopyrimidines
EP1778685B1 (de) 2004-08-02 2008-03-26 Schwarz Pharma Ag Carboxamide des indolizins und seiner aza- und diazaderivate
WO2006088246A1 (ja) 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Ｇｐｒ３４受容体機能調節剤
AR056876A1 (es) 2005-10-21 2007-10-31 Tanabe Seiyaku Co Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
WO2008045664A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
CA2705303A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
JP5578490B2 (ja) 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
EP2831074B1 (en) 2012-03-29 2016-09-14 Boehringer Ingelheim International GmbH Novel pyrazolopyrimidines as metabotropic glutamate 5 receptor antagonists for the treatment of psychiatric diseases
WO2014144455A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
CN103923105B (zh) 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
WO2016012896A1 (en) * 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
JP2018076234A (ja) 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
JP6894902B2 (ja) 2015-12-24 2021-06-30 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｃｆｔｒ制御因子及びこの使用方法
CN107286156A (zh) 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101993A1 (en) * 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
JP2011506474A (ja) * 2007-12-13 2011-03-03 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
WO2013087805A1 (en) * 2011-12-14 2013-06-20 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mglu5 receptors

Also Published As

Publication number Publication date
TW202233620A (zh) 2022-09-01
MX2023004712A (es) 2023-05-09
AU2021363703A9 (en) 2025-01-09
US20230080486A1 (en) 2023-03-16
KR20230096026A (ko) 2023-06-29
CN116348468A (zh) 2023-06-27
IL302247A (en) 2023-06-01
UY39482A (es) 2022-05-31
US20240199623A1 (en) 2024-06-20
AR123884A1 (es) 2023-01-18
CA3196061A1 (en) 2022-04-28
PY2193067A (es) 2022-06-20
WO2022084741A1 (en) 2022-04-28
CO2023006647A2 (es) 2023-05-29
EP4232451A1 (en) 2023-08-30
EP4232451A4 (en) 2024-11-06
US11827640B2 (en) 2023-11-28
AU2021363703A1 (en) 2023-06-22
CL2023001139A1 (es) 2023-11-17

Similar Documents

Publication Publication Date Title
JP2023547389A (ja) Ｃｆｔｒ調節剤化合物、その組成物及び用途
JP6087006B2 (ja) ビシクロ［３．２．１］オクチルアミド誘導体およびその使用
US11008308B2 (en) Quinazolinones as PARP14 inhibitors
CA2957046C (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
RU2642777C2 (ru) Производные 2-аминопиразина в качестве ингибиторов csf-1r киназы
CA2736281C (en) Tri-substituted pyrimidine compounds and their use as pde10 inhibitors
US11124494B2 (en) Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
TWI450893B (zh) Inhibition of prostaglandin D synthase in the piper Compounds
US20190389865A1 (en) SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
TWI851336B (zh) 腺苷受體拮抗劑化合物
CA3142002A1 (en) Targeted protein degradation of parp14 for use in therapy
AU2018208160A1 (en) HDAC6 selective inhibitors, preparation method therefor, and application thereof
KR20250023339A (ko) 페닐 트라이아졸 mll1-wdr5 단백질-단백질 상호작용 저해제
JP2006241089A (ja) ピロロピリミジン誘導体またはその塩
JP6100755B2 (ja) （２−ヘテロアリールアミノ）コハク酸誘導体
JP2018538355A (ja) ベンズアミド誘導体
WO2004004731A1 (en) 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix
WO2023067388A1 (en) Uses of cftr modulator and/or pde4 inhibitor compounds
JP2023503091A (ja) Ｔｒｐｖ４受容体リガンド
HK40089053A (zh) Cftr调节剂化合物、组合物及其用途
EP4522623A1 (en) Compositions useful for modulating splicing
JP2025530975A (ja) Ｉｒａｋ３結合剤としての置換イミダゾピラジン化合物
WO2026037286A1 (zh) 一类cGAS抑制剂、其制备方法和用途
CN118290330A (zh) 一种酰胺衍生物及其在医药上的应用
HK40078112B (zh) 氮杂稠环酰胺类化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260210